Jose Birriel
Pulmonary Disease · Miami, FLNPI 1104835099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 28.0% of the total. Reporting peaked in 2019 at $687 and has fallen 75.3% since, to $170 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 105 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$564
- GSK$481
- Philips North America LLC$248
- Insmed, Inc.$189
- Actelion Pharmaceuticals US, Inc.$162
- Mylan Specialty L.p.$143
- plus $224 from 7 others
Across 162 payments — averaging $3691.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$265K
- Sanofi US Services Inc.$223K
- Pfizer$64K
- Biohaven Pharmaceutical Holding Company Ltd.$45K
What the payments were for
- Food & beverage$1,91295%
- Education$995%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $564 |
| GSK | 29 | $481 |
| Philips North America LLC | 8 | $248 |
| Insmed, Inc. | 6 | $189 |
| Actelion Pharmaceuticals US, Inc. | 17 | $162 |
| Mylan Specialty L.p. | 7 | $143 |
| Novartis | 2 | $54 |
| Kaleo, Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Sanofi | 1 | $22 |
| Ambu Inc. | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $18 |
How this compares
$2,011 in reported general payments places this provider in the 40th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.